Patents by Inventor Benoit DELATOUR

Benoit DELATOUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 11124563
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 21, 2021
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Oligopeptide and methods for producing conjugates thereof
    Patent number: 10787505
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: September 29, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20200165329
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Application
    Filed: December 2, 2019
    Publication date: May 28, 2020
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20190077853
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Application
    Filed: September 25, 2018
    Publication date: March 14, 2019
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 10087245
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 2, 2018
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof
    Patent number: 9738712
    Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: August 22, 2017
    Assignees: F. HOFFMAN-LA ROCHE AG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CRNS), INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20170058022
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Application
    Filed: January 28, 2015
    Publication date: March 2, 2017
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • OLIGOPEPTIDE AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20160355575
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Application
    Filed: November 13, 2014
    Publication date: December 8, 2016
    Applicants: F. Hoffmann-La Roche AG, Centre National de la Recherche Scientifique, Commissariat A L'Energie Atomique et Aux Energies Alternatives
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST AMYLOID BETA AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20160347831
    Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.
    Type: Application
    Filed: November 13, 2014
    Publication date: December 1, 2016
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • Composition and method for treating cognitive impairments in down syndrom subjects
    Patent number: 9078874
    Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 14, 2015
    Assignee: Centre National De La Recherche Scientifique—CNRS
    Inventors: Marie-Caude Potier, Robert Dodd, Benoît Delatour, Jérôme Braudeau, Yann Herault
  • COMPOSITION AND METHOD FOR TREATING COGNITIVE IMPAIRMENTS IN DOWN SYNDROM SUBJECTS
    Publication number: 20120283248
    Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.
    Type: Application
    Filed: August 24, 2010
    Publication date: November 8, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Marie-Claude Potier, Robert Dodd, Benoît Delatour, Jérôme Braudeau, Yann Herault